JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB311162

Alexa Fluor® 647 Anti-Cytokeratin 19 antibody [EPNCIR127B]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Cytokeratin 19 antibody - conjugated to Alexa Fluor® 647.

View Alternative Names

Krt1-19, Krt19, Cytokeratin-19, Keratin-19, CK-19, K19

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • Unconjugated

    Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • Carrier free

    Anti-Cytokeratin 19 antibody [EPNCIR127B] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPNCIR127B

Isotype

IgG

Conjugation

Alexa Fluor® 647

Excitation/Emission

Ex: 650nm, Em: 665nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytokeratin 19 (CK19) also known as cytokera­tine 19 keratin 19 (KRT19) or CK19 is a type of intermediate filament found in epithelial cells. It serves as an essential component of the cytoskeleton. CK19 weighs approximately 40 kDa and is broadly expressed in simple epithelial tissues including liver intestine and various glandular epithelial cells. As a cytokeratin marker it often appears in combination with others like cytokeratin 17 in certain tissue types helping to maintain the structural integrity of cells.
Biological function summary

CK19 plays a role in maintaining the cytoskeletal framework that provides mechanical support and helps control cell size and shape. It is not part of a large protein complex but works closely with other cytokeratins to ensure the stability and resilience of epithelial tissues. The A53-B/A22.26 positive staining is often used to confirm its presence in clinical histopathology.

Pathways

CK19 connects to cellular processes especially involving the keratinization and epithelial cell differentiation pathways. It interacts with other cytokeratins including BA16 and KR17 to facilitate these processes. This interaction aids in modulating the dynamics of cytoskeletal rearrangement during cell movement division and differentiation.

CK19 overexpression is linked with certain cancers notably hepatocellular carcinoma and breast cancer. It can serve as a prognostic marker in these diseases often in conjunction with other markers like CK17. The involvement of CK19 in the epithelial-mesenchymal transition (EMT) process connects it to the progression and aggressiveness of tumors facilitated by interactions with proteins involved in EMT pathways.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle (By similarity).
See full target information Krt19

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com